BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20188679)

  • 1. Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells.
    Yashima S; Yoshizaki S; Shinoda K; Yoshida A; Kondo A; Mizuguchi H; Ryo A; Okuda K; Shimada M
    Vaccine; 2010 Apr; 28(18):3257-64. PubMed ID: 20188679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
    Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
    Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
    Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
    Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
    Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
    Bayer W; Schimmer S; Hoffmann D; Dittmer U; Wildner O
    Vaccine; 2008 Jan; 26(5):716-26. PubMed ID: 18160188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
    Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
    Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
    Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
    Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul JM; Barry R; Inchauspé G
    Vaccine; 2007 Oct; 25(42):7339-53. PubMed ID: 17875349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV.
    Jounai N; Okuda K; Kojima Y; Toda Y; Hamajima K; Ohba K; Klinman D; Xin KQ
    J Gene Med; 2003 Jul; 5(7):609-17. PubMed ID: 12825200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination.
    Aravindaram K; Kuo TY; Lan CW; Yu HH; Wang PH; Chen YS; Chen GH; Yang NS
    J Gene Med; 2009 Apr; 11(4):288-301. PubMed ID: 19194994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
    Calarota SA; Weiner DB; Lori F; Lisziewicz J
    Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus.
    Shinoda K; Xin KQ; Okuda K
    Vaccine; 2006 Apr; 24(15):2751-4. PubMed ID: 16417954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.